

Express Mail No.: EL 501 636 812 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: SAH *et al.*

Serial No.: 09/134,771

Group Art Unit: 1633

Filed: August 12, 1998

Examiner: Sumesh Kaushal

For: HUMAN MESENCEPHALON CELL  
LINES AND METHODS OF USE  
THEREFOR

Attorney Docket No.: 10624-009200!

FEB 09 2001  
TECH CENTER 1600/2900

RECEIVED

**TRANSMITTAL OF REVOCATION AND POWER OF ATTORNEY**

Assistant Commissioner for Patents  
Washington, D.C. 20231


Sir:

Applicants submit herewith an original Revocation and Power of Attorney for the above-identified application executed by David Anderson, Ph.D. and Chief Scientific Officer of Signal Pharmaceuticals, Inc. on November 20, 2000.

No fee is believed due. However, should any fee be required, please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150.

Respectfully submitted,

Date: February 6, 2001


  
Anthony M. Insogna 35,203  
(Reg. No.)

PENNIE & EDMONDS LLP  
1155 Avenue of the Americas  
New York, New York 10036-2711  
(212) 790-9090

*Enclosure*

Express Mail No. EL 501 636 812 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Application of:  
SAH, et al.

Serial No.: 09/134,771

Group Art Unit: 1633

Filed: August 12, 1998

Examiner: Sumesh Kaushal

For: HUMAN MESENCEPHALON CELL LINES AND METHODS OF USE THEREFOR

RECEIVED

FEB 09 2001

TECH CENTER 1600/2900

**REVOCATION AND POWER OF ATTORNEY**

Assistant Commissioner for Patents  
Washington, D.C. 20231

SIR:

Signal Pharmaceuticals, Inc., owner of the entire right, title and interest in, to and under the invention described and claimed in the above-identified patent application by virtue of an assignment (or assignments) recorded on October 21, 1998, at Reel 9537, Frame 0520, hereby revokes all previous powers of attorney and appoints S. Leslie Misrock (Reg. No. 18872), Berj A. Terzian (Reg. No. 20060), David Weild, III (Reg. No. 21094), Jonathan A. Marshall (Reg. No. 24614), Barry D. Rein (Reg. No. 22411), Stanton T. Lawrence, III (Reg. No. 25736), Charles E. McKenney (Reg. No. 22795), Philip T. Shannon (Reg. No. 24278), Francis E. Morris (Reg. No. 24615), Charles E. Miller (Reg. No. 24576), Gidon D. Stern (Reg. No. 27469), John J. Lauter, Jr. (Reg. No. 27814), Brian M. Poissant (Reg. No. 28462), Brian D. Coggio (Reg. No. 27624), Rory J. Radding (Reg. No. 28749), Stephen J. Harbulak (Reg. No. 29166), Donald J. Goodell (Reg. No. 19766), James N. Palik (Reg. No. 25510), Thomas E. Friebel (Reg. No. 29258), Laura A. Coruzzi (Reg. No. 30742), Jennifer Gordon (Reg. No. 30753), Allan A. Fanucci (Reg. No. 30256), Geraldine F. Baldwin (Reg. No. 31232), Victor N. Balancia (Reg. No. 31231), Samuel B. Abrams (Reg. No. 30605), Steven I. Wallach (Reg. No. 35402), Marcia H. Sundeen (Reg. No. 30893), Paul J. Zegger (Reg. No. 33821), Edmond R. Bannon (Reg. No. 32110), Bruce J. Barker (Reg. No. 33291), Adriane M. Antler (Reg. No. 32605), Thomas G. Rowan (Reg. No. 34419), James G. Markey (Reg. No. 31636), Thomas D. Kohler (Reg. No. 32797), Scott D. Stimpson (Reg. No. 33607), Gary S. Williams (Reg. No. 31066), William S. Galliani (Reg. No. 33885), Ann L. Gisolfi (Reg. No. 31956), Todd A. Wagner (Reg. No. 35399), Scott B. Familant (Reg. No. 35514), Kelly D. Talcott (Reg. No. 39582), Francis D. Cerrito (Reg. No. 38100), Anthony M. Insogna (Reg. No. 35203), Brian M. Rothery (Reg.

No. 35340), Brian D. Siff (Reg. No. 35679), and Alan Tenenbaum (Reg. No. 34939), all of Pennie & Edmonds LLP, whose addresses are 1155 Avenue of the Americas, New York, New York 10036, 1667 K Street N.W., Washington, DC 20006 and 3300 Hillview Avenue, Palo Alto, CA 94304, and each of them its attorneys, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

Please direct all future correspondence to Pennie & Edmonds LLP, located at 1155 Avenue of the Americas, New York, N.Y. 10036-2711, and direct all telephone calls to Pennie & Edmonds LLP at (212) 790-9090.

Respectfully submitted,

Date: November 20, 2000

By: David Anderson, Ph.D.  
Title: Chief Scientific Officer  
Signal Pharmaceuticals, Inc.

